Loading organizations...
Based in San Francisco, California, Elevian is a biotechnology company that develops therapeutic drugs targeting the GDF11 protein to treat age-related diseases and restore the body's regenerative capacities. The firm focuses on eliminating conditions associated with aging, such as neurological stroke, diabetes, obesity, and heart failure, through both the exogenous administration of recombinant proteins and the targeting of natural regulation mechanisms. Operating within the regenerative medicine sector, the enterprise bases its core approach on academic research demonstrating the rejuvenation effects of targeted GDF11 protein modulation. Elevian has raised $5.5 million in seed funding to advance its clinical research pipeline, securing financial backing from notable institutional investors including Bold Capital, Stanford StartX, Longevity Fund, and Kizoo Ventures. The biotechnology company was founded in the mid-2010s by Mark Allen, Amy Wagers, Lee Rubin, and Rich Lee.
Elevian has raised $60.5M across 3 funding rounds.
Elevian has raised $60.5M in total across 3 funding rounds.
Elevian has raised $60.5M across 3 funding rounds. Most recently, it raised $40.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 16, 2021 | $40M Series A | Caleb Bell | Bold Capital, JK Family Office, Leslie Ventures | Announced |
| Nov 26, 2020 | $15M Venture Round | Suzanne Fletcher | Bold Capital Partners, For Good Ventures, Kizoo Technology Capital, Lauder Partners, Longevity Fund, Savearth Fund, Western Technology Investment | Announced |
| Sep 5, 2018 | $5.5M Seed | — | — | Announced |
Elevian has raised $60.5M in total across 3 funding rounds.
Elevian's investors include Caleb Bell, Bold Capital, JK Family Office, Leslie Ventures, Suzanne Fletcher, Bold Capital Partners, For Good Ventures, Kizoo Technology Capital, Lauder Partners, Longevity Fund, SavEarth Fund, Western Technology Investment.
